NCT/Study#

NCT04904276 /

O-FOSTA-901 (Forte)

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients with Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients with Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

DISEASE GROUP:
ITP
current phase:
N/A
STUDY STATUS:
Accepting Patients
Location:
Little Silver, NJ
For More information: